Inhibition of human cytomegalovirus by trifluorothymidine.

AUTOR(ES)

Spector, S A

RESUMO

The antiviral activity of trifluorothymidine (TFT) singly and in combination with other antiviral agents against human cytomegalovirus (HCMV) was evaluated by using an infectious center plaque reduction assay. The 50% inhibitory dose of TFT against six different patient HCMV strains was 0.57 (+/- 0.24, standard deviation) microM and ranged from 0.32 to 0.97 microM. The 50% inhibitory dose for the laboratory-adapted HCMV strain, AD-169, was 2.1 microM. When TFT (0.17 microM) was combined with human fibroblast interferon (25 U/ml), the combination was additive against all four HCMV isolates evaluated. Synergism was observed when TFT (0.17 microM) was combined with phosphonoformic acid (25 microM) for all strains studied or with acyclovir (20 microM) for three of the four clinical HCMV strains tested. Each of the three antiviral agents, when combined with TFT, exhibited additive effects against strain AD-169. TFT at concentrations of 0.5, 1.7, and 3.5 microM had an increasing inhibitory effect on uninfected human embryonic lung fibroblast (HEL) cell growth over 72 h, with 16% growth inhibition at 3.5 microM after 3 days. There was no increased toxicity to growing HEL cells when the paired antiviral agent combinations were evaluated. These findings suggest that TFT may be useful singly or in combination with other antiviral agents in treating HCMV infections.

Documentos Relacionados

• Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine.
• Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine.
• Activity of trifluorothymidine against cytomegalovirus.
• Inhibition of human cytomegalovirus by combined acyclovir and vidarabine.
• Inhibition of mouse LM cell replication by trifluorothymidine: role of cytosolic deoxythymidine kinase.